Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22,416 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT).
Sheng X, Ye D, Zhou A, Yao X, Luo H, He Z, Wang Z, Zhao Y, Ji Z, Zou Q, He C, Guo J, Tu X, Liu Z, Shi B, Liu B, Chen P, Wei Q, Hu Z, Zhang Y, Jiang K, Zhou F, Wu D, Fu C, Li X, Wu B, Wang L, Qin S, Li G, Liu Y, Guo H, Chen K, Zhang D, Wang G, Ding L, Wang Y, Yuan X, Guo J. Sheng X, et al. Among authors: hu z. Eur J Cancer. 2023 Jan;178:205-215. doi: 10.1016/j.ejca.2022.10.025. Epub 2022 Nov 1. Eur J Cancer. 2023. PMID: 36459768 Free article. Clinical Trial.
Proxalutamide in metastatic castration-resistant prostate cancer: Primary analysis of a multicenter, randomized, open-label, phase 2 trial.
Zhou T, Qin S, Xu W, Tang S, Chen G, Li S, Hou J, Gao X, Shi G, Sun Z, Jin J, Chen L, Sun W, Liu B, Wang J, Meng Q, Wang D, Hu Z, He D, Yang Y, Song X, Fu C, Wang Y, Ye D, Zhang W. Zhou T, et al. Among authors: hu z. Int J Cancer. 2023 Aug 15;153(4):792-802. doi: 10.1002/ijc.34512. Epub 2023 Apr 10. Int J Cancer. 2023. PMID: 36919366 Clinical Trial.
Efficacy and safety of LY01005 versus goserelin implant in Chinese patients with prostate cancer: A multicenter, randomized, open-label, phase III, non-inferiority trial.
Gu C, Wang Z, Lin T, Liu Z, Han W, Zhang X, Liang C, Liu H, Yu Y, Xu Z, Liu S, Wang J, Jia L, Yao X, Liao W, Fu C, Tan Z, He G, Zhu G, Fan R, Yang W, Chen X, Liu Z, Zhong L, Shi B, Ding D, Chen S, Wei J, Yao X, Chen M, Lu Z, Xie Q, Hu Z, Wang Y, Guo H, Fan T, Liang Z, Chen P, Wang W, Xu T, Li C, Xing J, Liao H, He D, Wu Z, Yu J, Feng Z, Yang M, Dou Q, Zeng Q, Li Y, Gou X, Zhou G, Wang X, Zhu R, Zhang Z, Zhang B, Tan W, Qu X, Sun H, Gan T, Ye D. Gu C, et al. Among authors: hu z. Chin Med J (Engl). 2023 May 20;136(10):1207-1215. doi: 10.1097/CM9.0000000000002638. Epub 2023 Apr 3. Chin Med J (Engl). 2023. PMID: 37010251 Free PMC article. Clinical Trial.
Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Deprivation Therapy.
Li H, Zhang Y, Li D, Ma X, Xu K, Ding B, Li H, Wang Z, Ouyang W, Long G, Zeng J, Liu H, Yan L, Zhang Y, Liu Z, Guan W, Hu Z, Liu C, Wan J, Wang G, Pu X, Zhang M, Guo L, An R, Qi J, Guo A, Ye Z, Liu J, Zhang X, Xu H. Li H, et al. Among authors: hu z. Eur Urol. 2021 Jun;79(6):879-886. doi: 10.1016/j.eururo.2021.01.037. Epub 2021 Feb 10. Eur Urol. 2021. PMID: 33579577
22,416 results
You have reached the last available page of results. Please see the User Guide for more information.